FDA seeks public input on adulteration
This article was originally published in The Gold Sheet
Executive Summary
FDA plans to hold a public workshop this spring to begin the task of combating profit-motivated adulteration of regulated products. The workshop, with date and location to be announced shortly, will allow government agencies, industry stakeholders, academics and the public to advise FDA on issues surrounding fake ingredients and adulterated products, according to FDA Deputy Commissioner for Policy Randall Lutter. At a meeting of FDA's Science Board Feb. 24 in Gaithersburg, Md., Lutter acknowledged that firms may not alert regulators to adulteration "if they're able to control these problems at a relatively early stage," since raising flags could be "embarrassing," he said. Current FDA regulations require notifications about adulterations only when affected products have been shipped, a policy that members of Congress have criticized while discussing the agency's ongoing response to contaminated peanut ingredients. Lutter said the agency is striving to solicit information in both public and confidential forums. To collect information confidentially, FDA Feb. 23 launched a Web site that allows anonymous reporting of adulteration of regulated products to the agency's Office of Criminal Investigations at www.fda.gov/oci/contact.html
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.